Nanobiotix S.A.

NASDAQ:NBTX

Biotechnology

Healthcare
$26.90 -0.91%

-$0.33 today

Market cap
$1.37B
Beta
0.59
P/E (TTM)
-60.2
EPS (TTM)
-$0.51
52W Low $4.31High $57.14

Volume 0.04M

Average 0.08M

NBTX Common Stock

The par or stated value of issued common shares, plus paid-in capital where reported together.

Nanobiotix S.A.NASDAQ: NBTX

Common Stock · Q4 FY2025 · quarter ended Dec 2025

Common stock rises 2.0% from a year ago

Common stock stood at €1.45M at the end of Q4 FY2025, up 2.0% from a year earlier. Over 3 fiscal years it compounded at +11.6% a year.

Context

  • Common stock amounted to 2.1% of total assets at the end of Q4 FY2025, unchanged from a year earlier.
  • Common stock increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether common stock keeps rising in the next quarterly balance sheet after a +2.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterDec 2025
€1.45M— QoQ
Last fiscal yearDec 2025
€1.45M+2.0% YoY
Year agoDec 2024
€1.42M+2.0% since
Common Stock past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.0%——
1 year+2.0%——
3-year CAGR+11.6%——
5-year CAGR——
10-year CAGR——

Common Stock history

EUR · from the balance sheet

Latest · FY2025
1.45M EUR
Year-over-year change
+2.0%
4-year CAGR
+8.6%

Common Stock vs competitors

How NBTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +2.0% is the 8th highest of 10, against a peer median of +14.3%.
  • Common stock amounts to 2.1% of total assets for NBTX, versus a peer median of 0.0%.
NBTX Competitors
Common Stock for NBTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NBTXNanobiotix S.A.Dec 2025€1.45M EUR+2.0%+11.6%2.1%
CADLCandel Therapeutics, Inc.Mar 2026$733K USD+48.7%+23.8%0.4%
IBRXImmunityBio, Inc.Sep 2026$106K USD+8.2%+34.0%0.0%
SNDXSyndax Pharmaceuticals, Inc.Mar 2026$9K USD+0.0%+8.7%0.0%
KURAKura Oncology, Inc.Mar 2026$9K USD+12.5%+8.7%0.0%
BDTXBlack Diamond Therapeutics, Inc.Mar 2026$8K USD+14.3%+17.0%0.0%
TYRATyra Biosciences, Inc.Mar 2026$6K USD+20.0%+7.7%0.0%
IMMXImmix Biopharma, Inc.Mar 2026$5.31K USD+90.0%+56.0%0.0%
AVBPArriVent BioPharma, Inc. Common StockMar 2026$5K USD+25.0%—0.0%
PBYIPuma Biotechnology, Inc.Mar 2026$5K USD+0.0%+0.0%0.0%
NVCTNuvectis Pharma, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding NBTX) —+14.3%+12.8%0.0%

Competitors are the stored peer set for NBTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents83.92M41.39M75.28M49.74M52.75M
Short-term Investments00000
Net Receivables3.89M2.84M2.97M8.54M7.68M
Inventory02.98M200K00
Other Current Assets3.04M2.17M6.33M(1K)2K
Total Current Assets93.06M52.36M87.34M61.47M62.75M
Property, Plant & Equipment (Net)8.19M7.12M6.11M5.54M4.57M
Goodwill00000
Intangible Assets4K1K8K7K10K
Long-term Investments98K0000
Tax Assets00000
Other Non-current Assets421K291K443K406K434K
Total Non-current Assets8.71M7.41M6.56M5.95M5.01M
Total Assets101.77M59.77M93.9M67.42M67.76M
Account Payables5M4M6.7M4.48M6.58M
Short-term Debt7.08M3.6M3.82M3.66M3.1M
Tax Payables5.08M6.6M7.38M6.87M6.82M
Deferred Revenue16.77M16.57M18.23M18.16M36.22M
Other Current Liabilities5.39M7.41M760K8.27M430K
Total Current Liabilities36.85M37.94M49.87M58.94M57.51M
Long-term Debt32.42M44.04M41.66M43.01M89.12M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities318K270K325K28.21M3.73M
Total Non-current Liabilities38.13M48.88M45.87M74.19M94.74M
Total Liabilities74.98M86.81M95.74M133.12M152.24M
Common Stock1.05M1.05M1.41M1.42M1.45M
Retained Earnings(47M)(57.04M)(39.7M)(68.13M)(23.96M)
Accumulated OCI(182.82M)(226.58M)(276.07M)(311.51M)(376.15M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity26.79M(27.05M)(1.84M)(65.7M)(84.48M)
Total Debt46.02M53.17M50.57M50.9M95.32M
Net Debt(37.9M)11.78M(24.72M)1.17M42.57M

Nanobiotix S.A.

NASDAQ:NBTX

Intrinsic Alpha fair value

Locked

Current Price

$26.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.